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Opinion statement
Heart failure (HF) is increasingly recognized as the major complication of chemotherapy
regimens. Despite the development of modern targeted therapies such as monoclonal anti-
bodies, doxorubicin (DOXO), one of the most cardiotoxic anticancer agents, still remains the
treatment of choice for several solid and hematological tumors. The insurgence of cardiotox-
icity represents the major limitation to the clinical use of this potent anticancer drug. At the
molecular level, cardiac side effects of DOXO have been associated to mitochondrial dysfunc-
tion, DNA damage, impairment of iron metabolism, apoptosis, and autophagy dysregulation.
On these bases, the antioxidant and iron chelator molecule, dexrazoxane, currently represents
the unique FDA-approved cardioprotectant for patients treated with anthracyclines.
A less explored area of research concerns the impact of DOXO on cardiac metabolism. Recent
metabolomic studies highlight the possibility that cardiac metabolic alterations may critically
contribute to the development of DOXO cardiotoxicity. Among these, the impairment of
oxidative phosphorylation and the persistent activation of glycolysis, which are commonly
observed in response to DOXO treatment, may undermine the ability of cardiomyocytes tomeet
the energy demand, eventually leading to energetic failure. Moreover, increasing evidence
links DOXO cardiotoxicity to imbalanced insulin signaling and to cardiac insulin resistance.
Although anti-diabetic drugs, such as empagliflozin and metformin, have shown interesting
cardioprotective effects in vitro and in vivo in different models of heart failure, their
mechanism of action is unclear, and their use for the treatment of DOXO cardiotoxicity is still
unexplored.
This review article aims at summarizing current evidence of the metabolic derangements
induced by DOXO and at providing speculations on how key players of cardiac metabolism
could be pharmacologically targeted to prevent or cure DOXO cardiomyopathy.
Introduction
Doxorubicin (DOXO) is a highly effective chemothera-
peutic drug belonging to non-selective class I anthracy-
cline family [1], widely used for the treatment of several
cancers, such as solid tumors, acute leukemia, lympho-
mas, and breast cancer [2, 3]. However, its clinical use is
hampered by its cumulative and irreversible cardiotox-
icity, which leads tomyocardial dysfunctionmanifesting
as aberrant arrhythmias, ventricular dysfunction, and
congestive heart failure, even years after chemotherapy
cessation [4–6].
As the number of cancer survivors is steadily increas-
ing, the long-term side effects of DOXO administration
are becoming ever more apparent [7]. Despite the expo-
nential growth of the field of cardio-oncology in the last
decade, the molecular mechanisms underlying DOXO-
induced cardiotoxicity have not been fully elucidated yet
[8]. The finding that antioxidants fail to prevent DOXO-
induced cardiotoxicity has challenged the classical view
according to which oxidative stress is the main determi-
nant of the cardiac side effects of DOXO, suggesting the
involvement of additionalmechanisms [8, 9]. Among the
theories that have been proposed are mitochondrial dys-
function [10], DNAdamage [11], defects in iron handling
[10], apoptosis [12], and dysregulation of autophagy
[13–15].
Although the exact mechanism of DOXO cardiotoxic-
ity remains to be defined, mitochondrial damage and
accumulation of dysfunctional mitochondria have been
shown as key hallmarks of DOXO-induced cardiotoxic
effects [13]. Mitochondria constitute around 50% of the
cardiomyocyte volume and are vitally important for energy
generation. As DOXO accumulates in the inner mitochon-
drial membrane by binding cardiolipin, this perturbs mi-
tochondrial protein function and uncouples mitochondri-
al respiratory chain complexes, eventually impairing ATP
production [16]. Moreover, the ATP deficiency linked to
DOXO cardiotoxicity has been directly correlated to alter-
ations of mitochondrial energy metabolism and
bioenergetics.
The myocardium can fulfill the elevated metabolic
requests thanks to an incredible metabolic flexibility
according to which ATP can be generated starting from
a variety of energy substrates such as glucose, fatty acids,
and ketone bodies. Of note, build-up of each of these
carbon sources is associated with increased rates of car-
diovascular diseases [17], and, in general, metabolic
dysregulations play a critical role in the pathophysiology
of heart failure (HF) [18, 19].
The association between metabolic dysregulation
and cardiotoxicity has been demonstrated with different
cancer therapies, such as copanlisib in relapsed follicular
lymphoma [20], nilotinib in chronic myelogenous leu-
kemia [21, 22], and androgen deprivation (AD) in pros-
tate cancer [17], which were found associated to glucose
dysregulation and hyperglycemia, or increased choles-
terol level. Multiple studies have shown that AD therapy
consistently increase insulin resistance, total cholesterol,
and the rate of incident diabetes mellitus leading to
increased risk of myocardial infarction and sudden car-
diac death [23, 24]. However, less is known about the
cardiac metabolic dysregulations involved in DOXO
cardiotoxicity. Important clues come from a recent clin-
ical study conducted in breast cancer patients treated
with anthracyclines [25•], where a metabolite profiling
approach has been used to define the early metabolic
changes associated with the development of cardiotox-
icity. Patients who developed cardiotoxicity display
changes in citric acid and aconitic acid, along with an
increased level of purine and pyrimidine metabolites in
the plasma, that may be related to the systemic DNA
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damage induced by chemotherapy [25]. Of note, the
identification of early metabolic changes as well as the
measurement of circulating metabolites in the plasma
could provide insight into the mechanisms associated
with the development of DOXO cardiotoxicity.
In further support of the importance of exploring
metabolic changes linked to DOXO treatment, there is
growing evidence that drugs approved for the treatment
of metabolic diseases, such as diabetes, could protect
against anthracycline cardiotoxicity. Among them, two
anti-diabetic agents, metformin (MET) and empagliflo-
zin (EMPA), have shown promising results since, along
with their glucose-lowering effects, they protect against
the development of cardiometabolic diseases as well as
DOXO-related cardiotoxicity [26, 27]. Moreover,
empagliflozin, a SGLT2 inhibitor, exhibits protective
effects in DOXO-induced HF in mice without diabetes
[27•]. Taken together, these findings suggest that an
improved understanding of the mechanisms underlying
the regulation of cardiac metabolism in response to
DOXO treatment may lead to the identification of novel
pharmacological targets as well as the development of
new strategies to prevent the cardiotoxic effects of
DOXO in cancer patients.
Here, we focus on the description of the molecular
processes governing cardiac metabolism whose deregu-
lation has been linked to DOXO cardiotoxicity. More-
over, we discuss how the identification of key players of
cardiac metabolism may be instrumental to improve
and refine current therapeutic strategies.
DOXO cardiotoxicity and iron metabolism
Impairment of cellular ironmetabolism has been suggested as a main source of
reactive oxygen species (ROS) in DOXO-induced cardiotoxicity, a theory re-
ferred to as “ROS and iron hypothesis” [28, 29]. It has been demonstrated that
inside the cell DOXO is reduced to a cytotoxic semiquinone radical (SQ) that is
rapidly converted back to the original molecule usingO2 as an electron acceptor
[30, 31]. This process leads to superoxide formation that is detoxicated inH2O2,
either spontaneously or by superoxide dismutase activity (Fig.1). The cellular
pool of chelatable and redox-active iron, defined as labile iron pool (LIP),
strongly reacts with H2O2, generating ROS through Fenton reaction. Further-
more, LIP can directly interact with DOXO, creating DOXO-Fe complexes that
drive ROS production [32, 33]. In support of this evidence, it is reported that
DOXO interferes with mechanisms involved in cellular iron homeostasis. First,
DOXO modulates the mRNA maturation of transferrin receptor and ferritin,
through irreversible inactivation of the RNA-binding activity of iron regulatory
proteins 1 and 2 (IRP-1 and 2) (Fig. 1) [34, 35]. Moreover, DOXO disrupts the
cellular localization of iron, increasing iron/ferritin binding in the cytosol [36]
and reducing its release from cellular storages, such as mitochondria (Fig. 1)
[35]. In agreement, a mouse model of hereditary hemochromatosis (HH), in
which the lack of theHfe gene drives an aberrant iron accumulation in the heart
and other organs, is characterized by increased iron accumulation into mito-
chondria and high susceptibility to DOXO cardiotoxicity. Thus, in response to
DOXO treatment, the cytosolic iron concentration is maintained at physiolog-
ical levels through reduced mobilization of cellular storages and ferritin turn-
over, but its accumulation within mitochondria compromises mitochondrial
iron metabolism [10]. Ichikawa et al. demonstrated, both in vitro and in vivo,
that overexpression of the mitochondrial transporter ABCB8 facilitates the
efflux of iron frommitochondria, reduces ROS production, and protects against
DOXO-induced cardiotoxicity [10]. Iron accumulation into mitochondria has
been linked to ferroptosis, a recently described form of iron-dependent cell
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death, which is morphologically, biochemically, and genetically distinct from
apoptosis, necrosis, and autophagy. Ferroptosis is featured by mitochondria
iron accumulation and lipid peroxidation [37] and has been previously associ-
ated with other pathologies, such as cancer [38], stroke [39], and ischemia/
reperfusion injuries [40]. Fang and colleagues revealed for the first time the role
of ferroptosis in DOXO-induced cardiomyopathy. Mice defective for canonical
activators of necroptosis or apoptosis or both, Ripk3 −/−, Mlkl −/−, or Fadd
−/−Mlkl −/− respectively, showed typical hallmarks of ferroptosis in cardiomyo-
cytes after DOXO administration. This study demonstrates that ferroptosis is
triggered by heme oxygenase-1-mediated heme degradation through an Nrf2-
dependentmechanism that drastically induces iron overload intomitochondria
and ferroptosis activation [41].
Fig. 1. Metabolic changes induced by DOXO in cardiomyocytes. DOXO interferes with Fe2+ metabolism, leading to activation of
ferroptosis through ROS production, disruption of IRP-1 activity, and iron accumulation into mitochondria. These events are
hallmarks of mitochondrial dysfunction that leads to a block of fatty acid oxidation (FAO) and an increase in glycolysis, as a
consequence of AMPK inhibition. Acetyl-CoA carboxylase (ACC), a direct downstream target inhibited by AMPK, is overactivated and
catalyzes the formation of Malonyl-CoA, blocking FAO irreversibly. At the plasma membrane, DOXO promotes glucose uptake via
GLUT4 through insulin-mediated activation of AMPK and AKT2. In addition, DOXO increases the expression of GLUT1, an insulin-
independent glucose transporter, normally absent in the adult heart. Following the insulin desensitization induced by tumor-
secreted factors, AKT1 signaling is disrupted and promotes FOXO1 nuclear translocation, inducing the activation of the apoptotic
pathway through the expression of pro-apoptotic members of the Bcl-2 family. Finally, DOXO cardiotoxicity has been linked to
autophagy dysregulation. DOXO inhibits autophagy by activating mTOR or by blocking AMPK, resulting in accumulation of
undegraded autophagosomes and mitochondrial dysfunction with increased production of ROS. This figure was created with
BioRender.com.
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Strategies to reduce iron accumulation into mitochondria in response to
DOXO, using, for example, iron chelators, have been explored. Dexrazoxane is
the unique molecule approved by FDA for the treatment of DOXO cardiotox-
icity, for its dual activity as inhibitor of topoisomerase 2β (Top-2β) [42] and
iron chelator [41]. By limiting mitochondria iron accumulation in cardiomyo-
cytes [41•], dexrazoxane prevents the activation of apoptotic and ferroptotic
pathways. Nevertheless, several side effects have been linked to the use of
dexrazoxane, including the development of secondary malignancies, myelo-
suppression [43], and reduction of DOXO antitumoral efficacy as a conse-
quence of the inhibition of the topoisomerase 2 isoform expressed in cancer
cells, Top-2α [44, 45]. Nowadays, some of dexrazoxane-associated side effects
have been retracted [46, 47], and further studies elucidate that the cardiopro-
tective effect of dexrazoxane is mainly linked to its inhibition of Top-2β than its
iron-chelating property [48].
On the other hand, specific iron chelators, such as deferiprone [10], deferox-
amine [49], and deferasirox [50], failed to counteract DOXO-mediated cardio-
toxicity, probably due to their limited lipophilic properties and accessibility to
iron mitochondrial storage [51]. Instead, a mild protection against DOXO
toxicity has been documented with the small lipophilic iron chelator pyridoxal
isonicotinoyl hydrazone and its analogue [52]. Interestingly, the ferroptosis
inhibitor ferrostatin-1 has been proved to reduce iron-mediated lipid peroxida-
tion [53, 54]. Mice treated with ferrostatin-1 are protected against DOXO-
induced cardiotoxicity, suggesting the use of this molecule as a valid alternative
to dexrazoxane [41]. Overall, this evidence suggests that specific iron chelator
molecules fail to show a significant cardioprotective effect, likely because of
their inability to reach iron storage into mitochondria. In this scenario, the
inhibition of ferroptosis may represent a new promising approach to target one
of the multiple mechanisms driving DOXO cardiotoxicity.
Cardiac metabolic changes triggered by DOXO: a focus on fatty
acid oxidation and glycolysis
Cardiac metabolism is a highly sophisticated mechanism that in physiological
conditions uses fatty acids (FAs) as a major source for catabolic reactions while
switching to glycolysis in response to several pathological insults [18]. Despite
the glycolytic switch that represents an early compensatory event, persistent
glucose usage eventually turnsmaladaptive and leads to energetic failure, where
glycolysis and impaired mitochondrial function do not allow cardiomyocytes
to meet the cellular energy demand [55]. Studies with animal models have
shown that cardiac insulin resistance and metabolic modifications, such as
reducedmitochondrial oxidation of glucose, lactate, and fatty acids, are putative
early markers of heart stress [56]. In agreement, the inhibition of glucose uptake
consequent to insulin signaling desensitization has been identified as one of the
prevalent risk factors for HF, and disruption of physiological cardiac metabo-
lism adaptation has been associated with worse prognosis [57]. Despite these
observations, the use of insulin-sensitizing agents failed to show improvements
in patients and, on the contrary, has been associated with potential risk of
cardiac side effects [58]. In line with this evidence, Taegtmeyer and co-workers
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have proposed insulin resistance as a physiological adaptation to non-ischemic
heart damage, protecting cardiomyocytes from substrate overload in dysregu-
lated metabolic states [59]. Impairment of insulin signaling has been reported
to reduce glucose uptake and activate fatty acid oxidation in an AMPK-
dependent manner [60].
Similarly, cardiotoxic chemotherapeutic drugs have been shown to impair
intracellular mechanisms controlling cardiac metabolism [61•]. Specifically,
DOXO induces the systemic insulin resistance typical of type II diabetes, with
augmented serum triglyceride and blood glucose levels [62, 63], and, at the
same time, triggers massive cardiac glucose uptake [64, 65]. Furthermore,
DOXO has been demonstrated to affect gene expression involved in aerobic
fatty acid oxidation and anaerobic glycolysis (Fig. 1) [66].
A central role in this process is exerted by AMPK, themaster sensor of cellular
energy status, that acts as a “fuel gauge” [67]. AMPK triggers long-term catabolic
pathways that generate ATP, including fatty acid oxidation and glycolysis, while
downregulating processes that are dispensable for short-term cell survival, such
as the biosynthetic metabolism that rapidly consumes the ATP pool [68].
DOXO-mediated disruption of AMPK drives metabolic disarrangements and
cellular substrate overload [69]. Experimental evidence shows that DOXO-
induced AMPK inhibition increases glucose uptake after 2 weeks of treatment
[70], probably due to concomitant expression of GLUT1 [71], an insulin-
independent glucose transporter normally absent in the adult heart. Further-
more, Malonyl-CoA overproduction by acetyl coenzyme A carboxylase (ACC),
an enzyme directly inhibited by AMPK [72], irreversibly blocks FAO and
increases lipid synthesis and accumulation (Fig. 1) [73]. In agreement,
cardiomyocyte-specific overexpression of adipose triglyceride lipase limits FA
accumulation and shows a beneficial effect on cardiac function after DOXO
treatment [74].
Additionally, in response to cellular stress, AMPK inhibits the activity of
enzymes that reduce and consume ATP, such as creatine kinase [75]. DOXO
impairs the high-energy phosphate pool through direct inhibition of AMPK
[72] and creatine kinase (CK) system [76], reducing the phosphocreatine-to-
creatine (PCr/Cr), PCr-to-ATP (PCr/ATP), and ATP-to-ADP (ATP/ADP) ratios
[77]. In line with these observations, the recovery of AMPK activity exerts
beneficial effect on mitochondria, reducing oxidative stress and preserving
mitochondrial energy production [78].
The pivotal role of the AMPK pathway in the cardiac metabolic rearrange-
ments induced by DOXO has been recently confirmed in cardiomyocytes
derived from human-induced pluripotent stem cells (hi-PSCs), which have
been established as a powerful model for drug toxicity screening on cells
isolated from cancer patients under chemotherapy regimen [79••]. In these
cells, impairment of gene modulating cardiac metabolism is one of the main
effects of chemotherapeutic agents, including DOXO [80]. The use of specific
AMPK-inducing agents was proven effective in counteracting the bioenergetic
failure linked to the use of trastuzumab [80] and might be a new strategy to
counteract the development of cardiotoxicity during chemotherapy regimens.
Among these AMPK-restoring agents ismetformin, a hypoglycemic drug used to
treat patients with type 2 diabetes, which is known to trigger the AMPK pathway
in insulin-sensitive organs, such as the heart [81]. Notably, several studies have
reported the cardioprotective effects of metformin against DOXO-induced
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toxicity [26, 82, 83]. Furthermore, metformin also displays an AMPK-
dependent antitumoral activity [84], which makes this molecule a new prom-
ising agent to treat patients that suffer both HF and cancer.
Importantly, cancer and cardiovascular diseases are known to share several
risk factors, including aging, smoking, overweight, and physical inactivity, but
whether these two disease conditions are directly linked is still to be defined
[48, 85]. In this context, metabolic diseases have emerged as a common risk
factor for both cancer and heart failure [86–89]. Moreover, a clinical study has
reported that patients with comorbidities, such as diabetes, dyslipidemia, and
obesity, exhibit higher incidence of DOXO-related cardiotoxicity [9]. All these
indications suggest that metabolic diseases affect the clinical outcome of
patients subjected to DOXO treatment. In this context, insulin signaling plays
a fundamental role, in modulating both heart metabolism and cancer growth,
with AMPK being one of the main regulators.
In the following paragraph, we will describe how advanced cancer itself
dramatically interferes with the cardiac insulin pathway further exacerbating
drug-induced toxicity.
Insulin resistance at the crossroad of tumor growth and DOXO
cardiotoxicity
Metabolic diseases, such as obesity and diabetes, significantly increase the
incidence of HF in patients, where insulin resistance is a common risk factor.
Insulin desensitization occurring in this state drastically reduces the important
effects of insulin on cardiac tissue. Insulin receptor is widely expressed on the
surface of many cell types, including cardiomyocytes, where upon ligand bind-
ing and insulin receptor substrates (IRS) 1 and 2 are recruited. IRS1 more than
IRS2 is fundamental for regulation of the PI3K/Akt pathway and the MAP
kinase cascade, such as ERK, both involved in the control of metabolism and
cell survival [90]. Three members of the AKT family are known, AKT1, AKT2,
and AKT3, but how these isoforms differentially contribute to cardiac cell
function is not completely clear. It has been established that AKT1 is required
for cardiomyocyte survival, while AKT2 is essential for the modulation of genes
involved in cardiac metabolism. Indeed, AKT2 promotes glucose uptake
through the mobilization and fusion of GLUT4-containing vesicles to the
plasma membrane (Fig. 1) [90]. Despite the role of AKT during cardiac
stress condition is still debated, it is reported that short-term AKT
activation may exert cardioprotective effects, enhancing glycolysis and
reducing oxidative phosphorylation. Controversially, chronic and long-
term activity of AKT1 in the adult heart is associated with high risk of
cardiac complications and reduced mitochondrial functions. Following
insulin stimulation, AKT1 phosphorylates and blocks FOXO1 nuclear
translocation, inhibiting the expression of pro-apoptotic proteins belong-
ing to the Bcl-2 family (Fig. 1) [91]. FOXO1 has emerged as one of the
key players in chronic metabolic diseases, promoting hyperglycemia and
glucose intolerance [92]. In physiological conditions, pro-survival stimuli
was induced by insulin repress FOXO1 activity through PI3K/AKT1
pathway. Following stress stimuli, FOXO1 translocates in the nucleus
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and induces a negative feedback on insulin pathway through a JNK-
dependent mechanism that drastically reduces IRS-1 activity (Fig.1) [93].
Although the imbalance of insulin signaling has been extensively studied in
several models of obesity and type 2 diabetes, only a few studies have addressed
its role in DOXO-induced cardiotoxicity, and the underlying molecular mech-
anisms are still poorly understood. Recent studies demonstrate that aberrant
FOXO1 activity is responsible of DOXO-induced cardiotoxicity and its specific
pharmacological targeting has been shown to ameliorate the cardiac outcome
[94, 95].
In addition to chemotherapy, the tumor itself can negatively affect cardiac
insulin signaling. Interestingly, Thackeray et al. have reported that advanced
cancer contributes to the impairment of cardiac insulin signaling through
secretion of insulin-degrading enzymes, massive glucose adsorption, and re-
duced production of pancreatic insulin. In this scenario, other cancer-mediated
mechanisms, such as promotion of proteolysis by ubiquitin-proteasome and
autophagy-related lysosomal pathways, mitochondrial dysfunction, impair-
ment of catabolism and anabolism reactions, and release of the proinflamma-
tory cytokines such as IL-6 and TNF-α [96, 97], further contribute to increasing
the risk of heart failure development [91]. In agreement with the well-
established pro-survival role of insulin-stimulated AKT1 pathway in cardio-
myocytes, administration of low-dose insulin rescues cardiac function in
tumor-bearing mice by restoring AKT signaling and autophagy inhibition in
cardiomyocytes, without affecting cancer glucose uptake [98••]. Furthermore,
expression of a constitutively active form of AKT1 by adenoviral vector prevents
heart damage and protects mice from DOXO-induced cardiotoxicity [99],
suggesting that the lack of insulin-mediated AKT1 activation during cancer
progression could aggravate the cardiotoxicity induced by DOXO. In agree-
ment, previous report shows that insulin depletion is associated with increased
accumulation of DOXO into the heart and reduced cardiac function [100].
In addition to defective insulin signaling, the massive glucose uptake by the
tumor can deprive cardiac cells of a pivotal energetic source during stress
conditions [98]. Particularly, as described by Warburg in 1920, malignant cells
based their energy production on the use of glycolysis and generate lactate. This
metabolic adaptation, called “Warburg effect”, confers the ability to cancer cells
to survive in several stress conditions, including anaerobic environment of solid
tumor inner mass. In this scenario, the use of 2-deoxyglucose (2-DG), a glucose
analogue which blocks glycolysis, represent an interesting therapeutic strategy
to treat cancer. 2-DG is phosphorylated to 2-DG-6-P inside the cell by hexoki-
nase and cannot be further metabolized. It is thought that 2-DG-6-P competes
with glucose utilization into glycolysis and drastically reduces energy produc-
tion of cancer cells. Moreover, despite that 2-fluorodeoxy-D-glucose is a more
potent glycolysis inhibitor, themain effect of 2-DG is the inhibition of N-linked
glycosylation process, causing its high structural similarity to Mannose. The
block of oligosaccharide formation required for the assembling of structural
lipids andmaturation of glycoproteins has been observed to induce tumor cells’
death even in aerobic condition [101, 102]). Moreover, further studies were
conducted to investigate the combining of 2-DG with others antineoplastic
agents. In vivo evidence established that 2-DG co-treatment with adriamycin or
paclitaxel increased their antitumoral efficacy against osteosarcoma and non-
small cell lung cancers [103]. Previous work showed that caloric restriction
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treatment based on the administration of 2-DG prevents DOXO-mediated
cardiotoxicity through several mechanisms, including activation of AMPK-
dependent mechanism [104].
Of note, the targeted therapy with a 2-DG-based adriamycin complex
showed promising results, by specifically targeting tumor growth and, at the
same time, limiting the organ toxicity of anthracyclines in vivo [105]. Overall,
these findings suggest that the tumor itself negatively impacts on cardiac func-
tion through secreted factors that act in an endocrine manner and identify
dysregulation of the cardiac insulin pathway as a major mechanism whereby
the tumor negatively affects cardiac cell survival (Fig. 1).
Autophagy at the crossroad of metabolism and cell survival in
DOXO cardiotoxicity
Autophagy is a highly conserved process which is aimed to maintain cell and
tissue homeostasis, promoting the elimination of damaged and long-lived
organelles and misfolded proteins under both physiological and pathological
conditions [106, 13]. Importantly, autophagy plays an essential role in the
regulation of cellular metabolism, both in normal conditions and in the setting
of energy depletion, since it has been involved in the regulation and mobiliza-
tion of energy stores, such as lipids and glycogen [107]. Accumulating evidence
indicates that the cardiac side effects of DOXO may be closely related to a
dysregulation of autophagy signaling and an imbalance in cellular metabolism,
leading to intracellular Ca2+ accumulation, energy depletion, andmitochondri-
al dysfunction [108]. However, there is still controversy on whether DOXO
inhibits or activates autophagy and whether autophagy activation has a bene-
ficial or maladaptive role in this process [14].
Several studies have revealed that DOXO interferes with the initiation of the
autophagic process by modulating the two main regulatory pathways [109],
AMPK and mammalian target of rapamycin (mTOR). AMPK and mTOR pro-
mote and inhibit autophagy, respectively, by finely regulating the activity of the
autophagy activating kinase Ulk-1 (Fig. 1). AMPK is the main metabolic sensor
of the cell and is sensitive to changes in AMP:ATP ratio that is indicative of the
cellular energy state. In low energy state, activation of AMPK relieves mTOR-
inhibition of ULK1, leading to induction of autophagy [110]. Conversely, in the
presence of high levels of energy substrates, AMPK activity is antagonized by
mTOR which inhibits autophagy [111].
It has been shown that cardiac AMPK is inhibited in response to DOXO [72,
112]. Although the exact mechanism of such regulation remains elusive, r-
activation of AMPK has been proposed as a therapeutic strategy to counteract
DOXO-induced HF, and the cardioprotective effects of this approach have been
linked to reactivation of autophagy [113]. Importantly, promoting a negative
energy balance before DOXO treatment, i.e., via starvation or exercise, restores
AMPK signaling and autophagy and ultimately reduces DOXO-induced cardi-
otoxicity [114]. For instance, dietary restriction in rats treated with DOXO
modulates the ATP:AMP ratio inducing AMPK activation, increasing fatty acid
oxidation rates and ATP levels, and ultimately leads to improved cardiac
function [115]. In addition, AMPK activation, and the ensuing reduction in
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apoptosis and increase in autophagy, was further achieved in DOX-treated rat
neonatal cardiomyocytes with the caloric restriction mimetic 2-deoxyglucose
[104].
Mitochondrial dysfunction at the interplay of autophagy and metabolism
The exact link between autophagy andmetabolism regulation in the pathogenic
sequelae of DOXO cardiomyopathy is still to be defined. However, the prevail-
ing view is that DOXO-induced mitochondrial dysfunction and the ensuing
production of reactive oxygen species stand at the crossroad of these two cellular
processes. As a consequence of its accumulation within mitochondria, DOXO
uncouples mitochondrial respiratory chain complexes, eventually impairing
ATP production [16]. In keeping with this model, cardiomyocytes exposed to
DOXO exhibit low levels of ATP associated with dysregulation of autophagy
[116]. Thus, DOXO cardiotoxicity directly contributes to ATP deficiency, alter-
ing mitochondrial energy metabolism and bioenergetics [117], even though it
is still debated whether ATP deficiency is the trigger or the result of autophagy
deregulation.
Compelling evidence reveals that mitochondrial autophagy or mitophagy is
defective in models of DOXO-induced cardiotoxicity [118]. DOXO disrupts
cardiac mitochondrial autophagy by inhibiting lysosomal biogenesis and fu-
sion with autophagosomes, thus preventing proper digestion of damaged
mitochondria engulfed by autophagosomes [119, 120]. Recently, a compre-
hensive study by Abdullah et al. showed a direct association between autophagy
dysregulation and defects in mitochondrial respiration in the development of
DOXO-associated cardiomyopathy [118••]. In this study, both in vivo and
in vitro analyses showed that DOXO cardiotoxicity results in a gradual accu-
mulation of autophagosomes (Fig. 1); DOXO-induced autophagosome accu-
mulation, in turn, results in altered expression of proteins involved in the
regulation of mitochondrial dynamics and oxidative phosphorylation
(OXPHOS and PDH proteins) and in mitochondrial respiratory dysfunction
[118••]. Mitochondria isolated from both DOXO-treated hearts and intact
neonatal cardiomyocytes exposed to DOXO show decreased oxygen consump-
tion rate, indicating a suppression ofmitochondrial bioenergetics [118••]. Such
mitochondrial dysfunction could result from defects inmitochondrial substrate
uptake or in the activity of the entire TCA cycle, causing cardiomyocyte death by
ATP deprivation.
In agreement, another study reports that DOXO-treated cardiomyo-
cytes exhibit decreased levels of ATP which, in turn, activate autophagy
[121]. This study demonstrates that DOXO induces the production of 4-
hydroxynonenal (4-HNE), a product of lipid peroxidation which is toxic
to the heart and that mediates autophagy activation through lipid
peroxidation-derived aldehydes [121]. On the other hand, DOXO
reduces the expression of the mitochondrial aldehyde dehydrogenase
(ALDH2) [122], which has been shown to mediate cardioprotective
effects by reducing the production of 4-HNE and ROS [123, 124].
ALDH2 controls 4-HNE-induced autophagy via the regulation of
AMPK-Akt-mTOR-signaling pathway. The ALDH2 activator Alda-1 was
shown to prevent DOXO effects in neonatal cardiomyocytes, such as
downregulation of Akt phosphorylation and upregulation of autophagy
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proteins like Beclin-1, Atg5, and LC3-II [121]. In further support of a
link between ALDH2 and autophagy regulation in response to DOXO,
the autophagy inducer rapamycin could abolish the protective action of
Alda-1 against DOXO-induced cardiomyocyte dysfunction, whereas the
autophagy inhibitor 3-MA reduced DOXO cardiotoxicity [121]. A similar
study by Ge et al. demonstrated that ALDH2 knock-in mice treated with
DOXO had better cardiac function compared to DOXO-treated wild-type
mice [125]. Taken together, these results suggest that promoting ALDH2
expression and inhibition of 4-HNE-induced autophagy may be a plau-
sible approach to reduce DOXO-induced cardiac dysfunction.
Another possible link between mitochondrial metabolism dysfunction
and autophagy dysregulation in DOXO-induced cardiotoxicity could be
represented by intracellular calcium signaling [126, 127]. Decuypere
et al. reported intracellular Ca2+ as one of the regulators of autophagy
[128]. In healthy conditions, intracellular Ca2+ signaling suppresses
autophagy, while under stress conditions and low energy production
Ca2+ signaling is enhanced and stimulates autophagy. It has been
reported that DOXO perturbs the expression of Ca2+-handling proteins
and alters Ca2+ homeostasis, causing mitochondrial dysfunction and
apoptosis in the myocardium [126]. By disrupting Ca2+ handling,
DOXO dysregulates autophagy in human cardiac progenitor cells
(hCPCs), which are important regulators of myocardial homeostasis
[127]. In hCPCs, the cytotoxic effects of DOXO induce abnormal cyto-
solic Ca2+ accumulation which, in turn, disrupts mTOR-mediated regu-
lation of autophagy. Additionally, DOXO reduces the expression of the
autophagosome marker LC3 and of an anti-senescence marker, SMP30,
leading to reduced autophagosome formation and cellular viability,
respectively [127]. Accordingly, autophagy activation with the mTOR
inhibitor rapamycin rescues DOXO cardiotoxicity in hCPCs, with a
significant reduction in DOXO-mediated cytosolic Ca2+ accumulation
and restored autophagosome formation as well as SMP30 expression
[127].
Rapamycin has been also shown to alleviate the autophagic interruption
mediated by insulin-like growth factor II receptor α (IGF-IIRα) in DOXO-
treated H9c2 cells [129]. IGF-IIRα is a novel stress-inducible contributor to
cardiac damage which has been linked to DOXO-induced oxidative stress and
autophagy alteration [129]. Interestingly, IGF-IIRα overexpression in combina-
tion with DOXO treatment increases LC3 expression and perturbs autophago-
somal formation, impairing autophagy both in vitro in H9c2 cells and in vivo
in transgenic rat models [129].
Overall, these findings suggest that DOXO-mediated dysregulation of
autophagy drives mitochondrial dysfunction via different cytosolic and mito-
chondrial signaling axes and that restoring autophagy may be a valuable
therapeutic approach to target DOXO toxicity.
Metabolic agents as potential strategies to restore autophagy in DOXO cardiotoxicity
Currently, there are no specific treatments for DOXO cardiotoxicity, and
cancer patients experiencing cardiac issues are primarily treated with
standard heart failure medications, such as renin angiotensin system
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blockers and beta blockers. As discussed above, reactivation of AMPK
has been proposed as a therapeutic option to treat heart failure associ-
ated with different metabolic diseases. Intriguingly, the anti-diabetic
drug and AMPK activator, metformin, has been shown to improve
cardiac function in a diabetic OVE26 mouse model by increasing
autophagy activity [130]. Consistent with these findings, Zilinyi and
co-workers reported that co-administration of DOXO and metformin
increases autophagic activity and confers cardioprotection in a rat model
[26]. This study shows that metformin restores LC3 levels and induces
AMPK autophagy initiation, leading to improved cardiac function and
reduced DOXO cardiotoxicity [26].
Recently, new hypoglycemic drugs like SGLT2 inhibitors have been
shown to restore DOXO-mediated dysregulation of autophagy and to
improve cardiac function [131, 132•]. Among these, empagliflozin
(EMPA) has showed important cardioprotective effects in both diabetic
and non-diabetic in vivo models undergoing DOXO treatment [27].
Previous work with diabetic animal models treated with EMPA has led
to the hypothesis that EMPA prevents heart failure by improving ATP
generation and thereby enhancing cardiac efficiency [132•, 133]. Con-
sistently, Zucker diabetic fatty rats treated with EMPA show enhanced
cardiac autophagy via increased AMPK activation [132•]. Moreover,
EMPA enhances the cardiac energy pool by increasing cardiac energy
production from glucose and fatty acid oxidation, whereas it reduces
the cardiac content of sphingolipids and glycerophospholipids, major
factors contributing to insulin resistance-induced HF [132•]. Although
the effects of EMPA in DOXO-induced cardiotoxicity are still under
evaluation, preliminary results have shown improved cardiac function
in mice treated with EMPA [27]. Of note, EMPA showed a protective
effect against DOXO in H9C2 cells and in DOXO-treated mice [27].
From a mechanistic perspective, EMPA has been shown to increase
blood ketone levels, as beta hydroxybutyrate (βOHB) which, in turn,
improves cell viability and restores mitochondrial dysfunction, ulti-
mately reducing ROS generation and increasing intracellular ATP levels
in cardiomyocytes [27].
In conclusion, these observations unravel the possibility of repurposing
metabolic drugs to restore autophagy and mitochondrial metabolism to treat
or prevent DOXO cardiotoxicity.
The emerging role of gut microbiota-derived metabolites in
DOXO cardiotoxicity
Gut microbiota has been shown to be implicated in several cardiovas-
cular and metabolic diseases, such as atherosclerosis [134], dyslipidemia
[135], hypertension [136], chronic kidney disease [137], obesity [138],
type I [139] and type II [140] diabetes mellitus, as well as HF [141]. The
novel emerging approach of metagenomic has permitted to identify new
species of bacteria colonizing human gut that were not able to be
cultured in vitro [142] and allowed to compare the gut microbiota
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composition in patients with HF [141]. It is now well accepted that
microbiota-derived metabolites from dietary metabolism influence the
pathogenesis of cardiometabolic disorders [143]. These molecules are
secreted, degraded, or modified by different metabolic pathways active
in intestinal bacteria and can directly or indirectly affect the organism,
demonstrating how the gut microbiome can be considered a new and
independent endocrine organ in the host [144]. Among the most impor-
tant metabolites produced by gut microbiota, short chain fatty acids including
acetate, propionate, and butyrate have shown an interesting effect on cardiac
function in animal models [145]. The cardioprotective effects of butyrate are
primarily linked to its epigenetic action since it functions as a potent HDAC
inhibitor, and HDAC inhibitors are known to protect the heart from maladap-
tive hypertrophy and ischemic injuries [146–149]. Furthermore, many studies
conducted by Raphaeli and colleagues have elucidated the dual activity of
butyrate and its prodrugs which, on the one hand, synergize the antitumoral
activity of DOXO in cancer models and, on the other hand, protect the cardi-
omyocytes against DOXO-induced cardiotoxicity [150–152]. Recently, it has
been demonstrated for the first time that in vivo oral administration of FBA, a
novel synthetic derivative of butyrate, is able to protect the heart from DOXO-
induced cardiotoxicity, preventingmitochondrial dysfunction [153•]. Thus, the
use of GUT-microbiota-derived metabolite as nutraceutical may represent a
new promising therapeutic approach for DOXO cardiotoxicity.
Conclusion and future perspectives
The impact of major anticancer treatments on cardiac metabolism has long
been ignored and only recently has started to be investigated. The emerging
view is that cardiac metabolic alterations may be used not only as early
markers of iatrogenic cardiac injury but also as targets for pharmacological
interventions aimed at restraining the late-onset and chronic cardiotoxicity
associated to the use of anthracyclines. In this scenario, repurposing meta-
bolic drugs for the treatment of cardiotoxicity represents an intriguing ap-
proach. The new anti-diabetic drug empagliflozin has proven effective in
reducing glucose blood levels and, at the same time, rescuing heart function.
However, despite these promising cues, the molecular mechanisms behind
the cardioprotective effects of empagliflozin are still mysterious since the
putative molecular target of the drug, the sodium-glucose co-transporter-2, is
not expressed in cardiomyocytes. Other molecules employed for the treat-
ment of metabolic disorder, such as rosiglitazone, exhibited controversial
clinical results [58], thus highlighting the need of further work to clarify
these inconsistencies. On the other hand, compelling evidence is available in
support of the use of metformin, especially given its dual ability to modu-
late cardiac metabolism on the one side and to induce cancer cell death in
an AMPK-dependent manner on the other side. In perspective, the identifi-
cation of new and previously undescribed players specifically involved in the
metabolic adaptations induced by anthracyclines will pave the way towards
the design of new therapeutics that may prevent cardiotoxicity without
affecting the antineoplastic proprieties of the drug.
Curr. Treat. Options in Oncol.           (2021) 22:18 Page 13 of 21    18 
Acknowledgements
We gratefully acknowledge Enrico Bono for the help with figure preparation and Edoardo Bertero for helpful
discussion.
Funding
Open access funding provided by Università degli Studi di Torino within the CRUI-CARE Agreement.
Compliance with Ethical Standards
Conflict of Interest
Michele Russo declares that he has no conflict of interest.
Angela Della Sala declares that she has no conflict of interest.
Carlo Gabriele Tocchetti has received compensation fromAlere for service as a consultant and is listed as an inventor
on 2 heart failure patents.
Paolo Ettore Porporato declares that he has no conflict of interest.
Alessandra Ghigo is a co-founder and stakeholder of Kither Biotech, a pharmaceutical product company focused on
respiratory medicine not in conflict with statements made in this article.
Open Access
This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use,
sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate
credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if
changes were made. The images or other third party material in this article are included in the article's Creative
Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the
article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds
the permitted use, youwill need to obtain permission directly from the copyright holder. To view a copy of this
licence, visit http://creativecommons.org/licenses/by/4.0/.
References and Recommended Reading
Papers of particular interest, published recently, have been
highlighted as:
• Of importance
•• Of major importance
1. Carvalho C, Santos RX, Cardoso S, Correia S, Oliveira
PJ, Santos MS, et al. Doxorubicin: the good, the bad
and the ugly effect. Curr Med Chem.
2009;16(25):3267–85. https://doi.org/10.2174/
092986709788803312.
2. Weiss RB. The anthracyclines: will we ever find a better
doxorubicin? Semin Oncol. 1992;19(6):670–86.
3. Cortes-Funes H, Coronado C. Role of anthracyclines in
the era of targeted therapy. Cardiovasc Toxicol.
2007;7(2):56–60. https://doi.org/10.1007/s12012-
007-0015-3.
4. Singal PK, Li T, Kumar D, Danelisen I, Iliskovic N.
Adriamycin-induced heart failure: mechanism and
modulation. Mol Cell Biochem. 2000;207(1–2):77–
86. https://doi.org/10.1023/a:1007094214460.
5. CardinaleD,ColomboA, BacchianiG, Tedeschi I,Meroni
CA, Veglia F, et al. Early detection of anthracycline cardi-
otoxicity and improvement with heart failure therapy.
Circulation. 2015;131(22):1981–8. https://doi.org/10.
1161/CIRCULATIONAHA.114.013777.
6. Colombo A, Cipolla C, Beggiato M, Cardinale D. Car-
diac toxicity of anticancer agents. Curr Cardiol Rep.
   18 Page 14 of 21 Curr. Treat. Options in Oncol.           (2021) 22:18 
2013;15(5):362. https://doi.org/10.1007/s11886-013-
0362-6.
7. Ryan TD, Nagarajan R, Godown J. Cardiovascular tox-
icities in pediatric cancer survivors. Cardiol Clin.
2019;37(4):533–44. https://doi.org/10.1016/j.ccl.
2019.07.002.
8. Varricchi G, Ameri P, Cadeddu C, Ghigo A, Madonna R,
Marone G, et al. Antineoplastic drug-induced cardiotox-
icity: a redox perspective. Front Physiol. 2018;9:167.
https://doi.org/10.3389/fphys.2018.00167.
9. Vejpongsa P, Yeh ET. Prevention of anthracycline-
induced cardiotoxicity: challenges and opportunities. J
Am Coll Cardiol. 2014;64(9):938–45. https://doi.org/
10.1016/j.jacc.2014.06.1167.
10. Ichikawa Y, Ghanefar M, Bayeva M, Wu R, Khechaduri
A, Naga Prasad SV, et al. Cardiotoxicity of doxorubicin
ismediated throughmitochondrial iron accumulation.
J Clin Invest. 2014;124(2):617–30. https://doi.org/10.
1172/JCI72931.
11. Lyu YL, Kerrigan JE, Lin CP, Azarova AM, Tsai YC,
Ban Y, et al. Topoisomerase IIbeta mediated DNA
double-strand breaks: implications in doxorubicin
cardiotoxicity and prevention by dexrazoxane.
Cancer Res. 2007;67(18):8839–46. https://doi.org/
10.1158/0008-5472.CAN-07-1649.
12. Kobayashi S, Volden P, TimmD,Mao K, Xu X, LiangQ.
Transcription factor GATA4 inhibits doxorubicin-
induced autophagy and cardiomyocyte death. J Biol
Chem. 2010;285(1):793–804. https://doi.org/10.
1074/jbc.M109.070037.
13. Koleini N, Kardami E. Autophagy and mitophagy in
the context of doxorubicin-induced cardiotoxicity.
Oncotarget. 2017;8(28):46663–80. https://doi.org/10.
18632/oncotarget.16944.
14. Sala V, Della Sala A, Hirsch E, Ghigo A. Signaling
pathways underlying anthracycline cardiotoxicity.
Antioxid Redox Signal. 2020;32(15):1098–114.
https://doi.org/10.1089/ars.2020.8019.
15. Mercurio V, Pirozzi F, Lazzarini E, Marone G, Rizzo P,
Agnetti G, et al. Models of heart failure based on the
cardiotoxicity of anticancer drugs. J Card Fail.
2016;22(6):449–58. https://doi.org/10.1016/j.
cardfail.2016.04.008.
16. Goormaghtigh E, Chatelain P, Caspers J, Ruysschaert
JM. Evidence of a complex between adriamycin deriv-
atives and cardiolipin: possible role in cardiotoxicity.
Biochem Pharmacol. 1980;29(21):3003–10. https://
doi.org/10.1016/0006-2952(80)90050-7.
17. Grundy SM, Cleeman JI, Daniels SR, Donato KA, Eckel
RH, Franklin BA, et al. Diagnosis andmanagement of the
metabolic syndrome: an American Heart Association/
National Heart, Lung, and Blood Institute Scientific
Statement. Circulation. 2005;112(17):2735–52. https://
doi.org/10.1161/CIRCULATIONAHA.105.169404.
18.•• Bertero E, Maack C. Metabolic remodelling in heart
failure. Nat Rev Cardiol. 2018;15(8):457–70. https://
doi.org/10.1038/s41569-018-0044-6
Broad overview of the physiological processes of cardiac energy
metabolism and their pathological alterations in heart failure.
19.• McGarrah RW, Crown SB, Zhang GF, Shah SH, New-
gard CB. Cardiovascular metabolomics. Circ Res.
2018;122(9):1238–58. https://doi.org/10.1161/
CIRCRESAHA.117.311002
Discuss the current state of metabolomics, one of the newer
omics technologies, emerged as a powerful tool for under-
standing the metabolic changes that occur in heart failure and
ischemic heart disease.
20. DreylingM, Santoro A,Mollica L, Leppa S, Follows GA,
Lenz G, et al. Phosphatidylinositol 3-kinase inhibition
by copanlisib in relapsed or refractory indolent lym-
phoma. J Clin Oncol : official journal of the American
Society of Clinical Oncology. 2017;35(35):3898–905.
https://doi.org/10.1200/JCO.2017.75.4648.
21. Racil Z, Razga F, Drapalova J, Buresova L, Zackova D,
Palackova M, et al. Mechanism of impaired glucose
metabolism during nilotinib therapy in patients with
chronic myelogenous leukemia. Haematologica.
2013;98(10):e124–6. https://doi.org/10.3324/
haematol.2013.086355.
22. Breccia M, Muscaritoli M, Gentilini F, Latagliata R,
Carmosino I, Rossi Fanelli F, et al. Impaired fasting
glucose level as metabolic side effect of nilotinib in
non-diabetic chronic myeloid leukemia patients resis-
tant to imatinib. Leuk Res. 2007;31(12):1770–2.
https://doi.org/10.1016/j.leukres.2007.01.024.
23. Keating NL, O'Malley A, Freedland SJ, Smith MR. Diabe-
tes and cardiovascular disease during androgen depriva-
tion therapy: observational study of veterans with pros-
tate cancer. J Natl Cancer Inst. 2012;104(19):1518–23.
https://doi.org/10.1093/jnci/djs376.
24. Oka R, Utsumi T, Endo T, Yano M, Kamijima S, Kamiya
N, et al. Effect of androgen deprivation therapy on arterial
stiffness and serum lipid profile changes in patients with
prostate cancer: a prospective study of initial 6-month
follow-up. Int J Clin Oncol. 2016;21(2):389–96. https://
doi.org/10.1007/s10147-015-0891-7.
25.• Asnani A, Shi X, Farrell L, Lall R, Sebag IA, Plana JC, et al.
Changes in citric acid cycle and nucleoside metabolism
are associatedwith anthracycline cardiotoxicity in patients
with breast cancer. J Cardiovasc Transl Res. 2019. https://
doi.org/10.1007/s12265-019-09897-y
Clinical study reporting the role in patients of early metabolic
changes as insight into the mechanisms associated with the de-
velopment of chemotherapy-associated cardiotoxicity.
26.•• Zilinyi R, Czompa A, Czegledi A, Gajtko A, Pituk D,
Lekli I, et al. The cardioprotective effect ofmetformin in
doxorubicin-induced cardiotoxicity: the role of
autophagy. Molecules. 2018;23(5):1184. https://doi.
org/10.3390/molecules23051184
Examine the protective role of metformin and its effect on
autophagy in doxorubicin-induced cardiotoxicity.
27.• •OhCM, Cho S, Jang JY, KimH, Chun S, ChoiM, et al.
Cardioprotective potential of an SGLT2 inhibitor
against doxorubicin-induced heart failure. Korean Circ
J. 2019;49(12):1183–95. https://doi.org/10.4070/kcj.
2019.0180
First study reporting the cardioprotective effects of SGLT2
inhibitors in DOXO-induced HF in mice. Treatment with
Curr. Treat. Options in Oncol.           (2021) 22:18 Page 15 of 21    18 
empagliflozin prevented the development of DOXO-
cardiotoxicity by switching fuel consumption and activating
autophagy.
28. Berthiaume JM, Wallace KB. Adriamycin-induced oxi-
dative mitochondrial cardiotoxicity. Cell Biol Toxicol.
2007;23(1):15–25. https://doi.org/10.1007/s10565-
006-0140-y.
29. Myers C. The role of iron in doxorubicin-induced car-
diomyopathy. Semin Oncol. 1998;25(4 Suppl 10):10–
4.
30. Keizer HG, Pinedo HM, Schuurhuis GJ, Joenje H.
Doxorubicin (adriamycin): a critical review of free
radical-dependent mechanisms of cytotoxicity. Phar-
macol Ther. 1990;47(2):219–31. https://doi.org/10.
1016/0163-7258(90)90088-j.
31. Riddick DS, Lee C, Ramji S, Chinje EC, Cowen RL,
Williams KJ, et al. Cancer chemotherapy and drug
metabolism. Drug Metab Dispos. 2005;33(8):1083–
96. https://doi.org/10.1124/dmd.105.004374.
32. Xu X, Persson HL, Richardson DR. Molecular pharma-
cology of the interaction of anthracyclines with iron.
Mol Pharmacol. 2005;68(2):261–71. https://doi.org/
10.1124/mol.105.013383.
33. Myers CE, Gianni L, Simone CB, Klecker R, Greene R.
Oxidative destruction of erythrocyte ghost membranes
catalyzed by the doxorubicin-iron complex. Biochem-
istry. 1982;21(8):1707–12. https://doi.org/10.1021/
bi00537a001.
34. Minotti G, Ronchi R, Salvatorelli E, Menna P, Cairo G.
Doxorubicin irreversibly inactivates iron regulatory
proteins 1 and 2 in cardiomyocytes: evidence for dis-
tinct metabolic pathways and implications for iron-
mediated cardiotoxicity of antitumor therapy. Cancer
Res. 2001;61(23):8422–8.
35. Xu X, Sutak R, Richardson DR. Iron chelation by clin-
ically relevant anthracyclines: alteration in expression
of iron-regulated genes and atypical changes in intra-
cellular iron distribution and trafficking. Mol Pharma-
col. 2008;73(3):833–44. https://doi.org/10.1124/mol.
107.041335.
36. Kwok JC, Richardson DR. Anthracyclines induce accu-
mulation of iron in ferritin in myocardial and neo-
plastic cells: inhibition of the ferritin iron mobilization
pathway. Mol Pharmacol. 2003;63(4):849–61. https://
doi.org/10.1124/mol.63.4.849.
37. Stockwell BR, Friedmann Angeli JP, Bayir H, Bush AI,
Conrad M, Dixon SJ, et al. Ferroptosis: a regulated cell
death nexus linking metabolism, redox biology, and
disease. Cell. 2017;171(2):273–85. https://doi.org/10.
1016/j.cell.2017.09.021.
38. Mou Y, Wang J, Wu J, He D, Zhang C, Duan C, et al.
Ferroptosis, a new form of cell death: opportunities
and challenges in cancer. J Hematol Oncol.
2019;12(1):34. https://doi.org/10.1186/s13045-019-
0720-y.
39. Tuo QZ, Lei P, Jackman KA, Li XL, Xiong H, Li XL, et al.
Tau-mediated iron export prevents ferroptotic damage
after ischemic stroke. Mol Psychiatry.
2017;22(11):1520–30. https://doi.org/10.1038/mp.
2017.171.
40. Linkermann A, Skouta R, Himmerkus N, Mulay SR,
Dewitz C, De Zen F, et al. Synchronized renal tubular
cell death involves ferroptosis. Proc Natl Acad Sci U S
A. 2014;111(47):16836–41. https://doi.org/10.1073/
pnas.1415518111.
41.•• Fang X, Wang H, Han D, Xie E, Yang X, Wei J, et al.
Ferroptosis as a target for protection against cardiomy-
opathy. Proc Natl Acad Sci U S A. 2019;116(7):2672–
80. https://doi.org/10.1073/pnas.1821022116
First evidence that inhibition of Ferroptosis protects from heart
dynsfuction.
42. Zhang S, Liu X, Bawa-Khalfe T, Lu LS, Lyu YL, Liu LF,
et al. Identification of the molecular basis of
doxorubicin-induced cardiotoxicity. Nat Med.
2012;18(11):1639–42. https://doi.org/10.1038/nm.
2919.
43. Tebbi CK, London WB, Friedman D, Villaluna D, De
Alarcon PA, Constine LS, et al. Dexrazoxane-associated
risk for acute myeloid leukemia/myelodysplastic syn-
drome and other secondary malignancies in pediatric
Hodgkin's disease. J Clin Oncol. 2007;25(5):493–500.
https://doi.org/10.1200/JCO.2005.02.3879.
44. Deng S, Yan T, Nikolova T, Fuhrmann D, Nemecek A,
Godtel-Armbrust U, et al. The catalytic topoisomerase
II inhibitor dexrazoxane induces DNA breaks, ATF3
and the DNA damage response in cancer cells. Br J
Pharmacol. 2015;172(9):2246–57. https://doi.org/10.
1111/bph.13046.
45. Swain SM, Whaley FS, Gerber MC,Weisberg S, York M,
Spicer D, et al. Cardioprotection with dexrazoxane for
doxorubicin-containing therapy in advanced breast
cancer. J Clin Oncol. 1997;15(4):1318–32. https://doi.
org/10.1200/JCO.1997.15.4.1318.
46. Reichardt P, Tabone MD, Mora J, Morland B, Jones RL.
Risk-benefit of dexrazoxane for preventing
anthracycline-related cardiotoxicity: re-evaluating the
European labeling. Future Oncol. 2018;14(25):2663–
76. https://doi.org/10.2217/fon-2018-0210.
47. Seif AE, Walker DM, Li Y, Huang YS, Kavcic M, Torp K,
et al. Dexrazoxane exposure and risk of secondary acute
myeloid leukemia in pediatric oncology patients.
Pediatr Blood Cancer. 2015;62(4):704–9. https://doi.
org/10.1002/pbc.25043.
48. Bures J, Jirkovska A, Sestak V, Jansova H, Karabanovich
G, Roh J, et al. Investigation of novel dexrazoxane
analogue JR-311 shows significant cardioprotective
effects through topoisomerase IIbeta but not its iron
chelating metabolite. Toxicology. 2017;392:1–10.
https://doi.org/10.1016/j.tox.2017.09.012.
49. Popelova O, Sterba M, Simunek T, Mazurova Y, Gun-
cova I, Hroch M, et al. Deferiprone does not protect
against chronic anthracycline cardiotoxicity in vivo. J
Pharmacol Exp Ther. 2008;326(1):259–69. https://doi.
org/10.1124/jpet.108.137604.
50. Hasinoff BB, Patel D, Wu X. The oral iron chelator
ICL670A (deferasirox) does not protect myocytes
against doxorubicin. Free Radic Biol Med.
   18 Page 16 of 21 Curr. Treat. Options in Oncol.           (2021) 22:18 
2003;35(11):1469–79. https://doi.org/10.1016/j.
freeradbiomed.2003.08.005.
51. Zanninelli G, Glickstein H, Breuer W, Milgram P, Bris-
sot P, Hider RC, et al. Chelation and mobilization of
cellular iron by different classes of chelators. Mol
Pharmacol. 1997;51(5):842–52. https://doi.org/10.
1124/mol.51.5.842.
52. Schroterova L, Kaiserova H, Baliharova V, Velik J, Gersl
V, Kvasnickova E. The effect of new lipophilic chelators
on the activities of cytosolic reductases and P450 cyto-
chromes involved in the metabolism of anthracycline
antibiotics: studies in vitro. Physiol Res.
2004;53(6):683–91.
53. Miotto G, Rossetto M, Di Paolo ML, Orian L, Vener-
ando R, Roveri A, et al. Insight into the mechanism of
ferroptosis inhibition by ferrostatin-1. Redox Biol.
2020;28:101328. https://doi.org/10.1016/j.redox.
2019.101328.
54. Dixon SJ, Lemberg KM, Lamprecht MR, Skouta R,
Zaitsev EM, Gleason CE, et al. Ferroptosis: an iron-
dependent form of nonapoptotic cell death. Cell.
2012;149(5):1060–72. https://doi.org/10.1016/j.cell.
2012.03.042.
55. Stanley WC, Recchia FA, Lopaschuk GD. Myocardial
substrate metabolism in the normal and failing heart.
Physiol Rev. 2005;85(3):1093–129. https://doi.org/
10.1152/physrev.00006.2004.
56. Zhang L, Jaswal JS, Ussher JR, Sankaralingam S, Wagg
C, Zaugg M, et al. Cardiac insulin-resistance and de-
creased mitochondrial energy production precede the
development of systolic heart failure after pressure-
overload hypertrophy. Circ Heart Fail.
2013;6(5):1039–48. https://doi.org/10.1161/
CIRCHEARTFAILURE.112.000228.
57. Witteles RM, Fowler MB. Insulin-resistant cardiomy-
opathy clinical evidence, mechanisms, and treatment
options. J Am Coll Cardiol. 2008;51(2):93–102.
https://doi.org/10.1016/j.jacc.2007.10.021.
58. Nissen SE, Wolski K. Effect of rosiglitazone on the risk
of myocardial infarction and death from cardiovascu-
lar causes. N Engl J Med. 2007;356(24):2457–71.
https://doi.org/10.1056/NEJMoa072761.
59. Taegtmeyer H, Beauloye C, Harmancey R, Hue L. In-
sulin resistance protects the heart from fuel overload in
dysregulated metabolic states. Am J Physiol Heart Circ
Physiol. 2013;305(12):H1693–7. https://doi.org/10.
1152/ajpheart.00854.2012.
60. Long YC, Cheng Z, Copps KD, White MF. Insulin re-
ceptor substrates Irs1 and Irs2 coordinate skeletal
muscle growth and metabolism via the Akt and AMPK
pathways. Mol Cell Biol. 2011;31(3):430–41. https://
doi.org/10.1128/MCB.00983-10.
61.• • Deidda M, Mercurio V, Cuomo A, Noto A, Mercuro
G, Cadeddu DC. Metabolomic perspectives in anti-
blastic cardiotoxicity and cardioprotection. Int J Mol
Sci. 2019;20(19):4928. https://doi.org/10.3390/
ijms20194928
Recent overview that describes metabolomic approach as a
potential and practical tool to investigate the impact of
chemotherapy-induced cardiotoxicity.
62. Arunachalam S, Tirupathi Pichiah PB, Achiraman S.
Doxorubicin treatment inhibits PPARgamma and may
induce lipotoxicity by mimicking a type 2 diabetes-like
condition in rodent models. FEBS Lett.
2013;587(2):105–10. https://doi.org/10.1016/j.
febslet.2012.11.019.
63. de Lima Junior EA, Yamashita AS, Pimentel GD, De
Sousa LG, Santos RV, Goncalves CL, et al. Doxorubicin
caused severe hyperglycaemia and insulin resistance,
mediated by inhibition in AMPk signalling in skeletal
muscle. J Cachexia Sarcopenia Muscle. 2016;7(5):615–
25. https://doi.org/10.1002/jcsm.12104.
64.•• Bauckneht M, Ferrarazzo G, Fiz F, Morbelli S, Sarocchi
M, Pastorino F, et al. Doxorubicin effect onmyocardial
metabolism as a prerequisite for subsequent develop-
ment of cardiac toxicity: a translational (18)F-FDG
PET/CT observation. J Nucl Med. 2017;58(10):1638–
45. https://doi.org/10.2967/jnumed.117.191122
Translational study that indicates basal cardiac metabolism as
predictive factor doxorubicin-induced cardiotoxicity.
65. Sambuceti G,Morbelli S, Cossu V,Marini C, Bauckneht
M. Reply: doxorubicin effect on myocardial metabo-
lism as a prerequisite for subsequent development of
cardiac toxicity: are there unsuspected confounders? J
Nucl Med. 2018;59(4):713–4. https://doi.org/10.
2967/jnumed.117.206797.
66. Carvalho RA, Sousa RP, Cadete VJ, Lopaschuk GD,
Palmeira CM, Bjork JA, et al. Metabolic remodeling
associated with subchronic doxorubicin cardiomyop-
athy. Toxicology. 2010;270(2–3):92–8. https://doi.
org/10.1016/j.tox.2010.01.019.
67. Hardie DG, Carling D. The AMP-activated protein
kinase–fuel gauge of the mammalian cell? Eur J Bio-
chem. 1997;246(2):259–73. https://doi.org/10.1111/
j.1432-1033.1997.00259.x.
68. Hardie DG. AMP-activated protein kinase: a master
switch in glucose and lipid metabolism. Rev Endocr
Metab Disord. 2004;5(2):119–25. https://doi.org/10.
1023/B:REMD.0000021433.63915.bb.
69. Gratia S, Kay L, Potenza L, Seffouh A, Novel-Chate V,
Schnebelen C, et al. Inhibition of AMPK signalling by
doxorubicin: at the crossroads of the cardiac responses
to energetic, oxidative, and genotoxic stress. Cardiovasc
Res. 2012;95(3):290–9. https://doi.org/10.1093/cvr/
cvs134.
70. Bulten BF, Sollini M, Boni R, Massri K, de Geus-Oei LF,
van Laarhoven HWM, et al. Cardiac molecular path-
ways influenced by doxorubicin treatment in mice. Sci
Rep. 2019;9(1):2514. https://doi.org/10.1038/
s41598-019-38986-w.
71. Hrelia S, Fiorentini D, Maraldi T, Angeloni C, Bordoni
A, Biagi PL, et al. Doxorubicin induces early lipid per-
oxidation associated with changes in glucose transport
in cultured cardiomyocytes. Biochim Biophys Acta.
2002;1567(1–2):150–6. https://doi.org/10.1016/
s0005-2736(02)00612-0.
Curr. Treat. Options in Oncol.           (2021) 22:18 Page 17 of 21    18 
72. Tokarska-Schlattner M, Zaugg M, da Silva R, Lucchi-
netti E, Schaub MC, Wallimann T, et al. Acute toxicity
of doxorubicin on isolated perfused heart: response of
kinases regulating energy supply. Am J Physiol Heart
Circ Physiol. 2005;289(1):H37–47. https://doi.org/10.
1152/ajpheart.01057.2004.
73. Long YC, Zierath JR. AMP-activated protein kinase sig-
naling in metabolic regulation. J Clin Invest.
2006;116(7):1776–83. https://doi.org/10.1172/
JCI29044.
74. Nagendran J, Kienesberger PC, Pulinilkunnil T, Zor-
doky BN, Sung MM, Kim T, et al. Cardiomyocyte spe-
cific adipose triglyceride lipase overexpression prevents
doxorubicin induced cardiac dysfunction in female
mice. Heart. 2013;99(14):1041–7. https://doi.org/10.
1136/heartjnl-2013-303843.
75. Ponticos M, Lu QL, Morgan JE, Hardie DG, Partridge
TA, Carling D. Dual regulation of the AMP-activated
protein kinase provides a novel mechanism for the
control of creatine kinase in skeletal muscle. EMBO J.
1998;17(6):1688–99. https://doi.org/10.1093/emboj/
17.6.1688.
76. Gupta A, Rohlfsen C, Leppo MK, Chacko VP, Wang Y,
Steenbergen C, et al. Creatine kinase-overexpression
improves myocardial energetics, contractile dysfunc-
tion and survival inmurine doxorubicin cardiotoxicity.
PLoS One. 2013;8(10):e74675. https://doi.org/10.
1371/journal.pone.0074675.
77. Octavia Y, Tocchetti CG, Gabrielson KL, Janssens S,
Crijns HJ, Moens AL. Doxorubicin-induced cardiomy-
opathy: from molecular mechanisms to therapeutic
strategies. J Mol Cell Cardiol. 2012;52(6):1213–25.
https://doi.org/10.1016/j.yjmcc.2012.03.006.
78. Liu D, Ma Z, Di S, Yang Y, Yang J, Xu L, et al.
AMPK/PGC1alpha activation by melatonin attenuates
acute doxorubicin cardiotoxicity via alleviating mito-
chondrial oxidative damage and apoptosis. Free Radic
Biol Med. 2018;129:59–72. https://doi.org/10.1016/j.
freeradbiomed.2018.08.032.
79.•• Sharma A,McKeithanWL, Serrano R, Kitani T, Burridge
PW, Del Alamo JC, et al. Use of human induced plu-
ripotent stem cell-derived cardiomyocytes to assess
drug cardiotoxicity. Nat Protoc. 2018;13(12):3018–41.
https://doi.org/10.1038/s41596-018-0076-8
Assessment of a new biological platform to investigate the
drug-induced cardiotoxicity in human induced pluripotent
stem cell-derived cardiomyocytes.
80. Cunha-Oliveira T, Ferreira LL, Coelho AR, Deus CM,
Oliveira PJ. Doxorubicin triggers bioenergetic failure
and p53 activation in mouse stem cell-derived cardio-
myocytes. Toxicol Appl Pharmacol. 2018;348:1–13.
https://doi.org/10.1016/j.taap.2018.04.009.
81. Musi N, Hirshman MF, Nygren J, Svanfeldt M, Baven-
holm P, RooyackersO, et al. Metformin increases AMP-
activated protein kinase activity in skeletal muscle of
subjects with type 2 diabetes. Diabetes.
2002;51(7):2074–81. https://doi.org/10.2337/
diabetes.51.7.2074.
82. Asensio-Lopez MC, Sanchez-Mas J, Pascual-Figal DA,
Abenza S, Perez-Martinez MT, Valdes M, et al. In-
volvement of ferritin heavy chain in the preventive
effect of metformin against doxorubicin-induced car-
diotoxicity. Free Radic Biol Med. 2013;57:188–200.
https://doi.org/10.1016/j.freeradbiomed.2012.09.
009.
83.•• Kitani T, Ong SG, Lam CK, Rhee JW, Zhang JZ, Oiko-
nomopoulos A, et al. Human-induced pluripotent
stem cell model of trastuzumab-induced cardiac dys-
function in patients with breast cancer. Circulation.
2019;139(21):2451–65. https://doi.org/10.1161/
CIRCULATIONAHA.118.037357
Evaluation of Trastuzumab-induced cardiotoxicity on human
induced pluripotent stem cell-model derived from patients.
84. Choi YK, Park KG. Metabolic roles of AMPK and
metformin in cancer cells. Mol Cell.
2013;36(4):279–87. https://doi.org/10.1007/
s10059-013-0169-8.
85. Lopez-Otin C, Blasco MA, Partridge L, Serrano M,
Kroemer G. The hallmarks of aging. Cell.
2013;153(6):1194–217. https://doi.org/10.1016/j.
cell.2013.05.039.
86.•• Aboumsallem JP, Moslehi J, de Boer RA. Reverse car-
dio-oncology: cancer development in patients with
cardiovascular disease. J Am Heart Assoc.
2020;9(2):e013754. https://doi.org/10.1161/JAHA.
119.013754
Recent overview on Heart Failure-associated factors inducing
Cancer.
87.•• de Boer RA, Meijers WC, van der Meer P, van Veld-
huisen DJ. Cancer and heart disease: associations and
relations. Eur J Heart Fail. 2019;21(12):1515–25.
https://doi.org/10.1002/ejhf.1539
Emerging evidence of cancer and heart diseases interplay.
88.•• Meijers WC, de Boer RA. Common risk factors for heart
failure and cancer. Cardiovasc Res. 2019;115(5):844–
53. https://doi.org/10.1093/cvr/cvz035
Highlighting of common risk factors shared between heart
failure and cancer.
89.• Ameri P, Canepa M, Anker MS, Belenkov Y, Bergler-
Klein J, Cohen-Solal A, et al. Cancer diagnosis in
patients with heart failure: epidemiology, clinical
implications and gaps in knowledge. Eur J Heart Fail.
2018;20(5):879–87. https://doi.org/10.1002/ejhf.
1165
Guideline of cancer diagnosis in patients with heart failure.
90. DeBosch B, Sambandam N, Weinheimer C, Courtois
M, Muslin AJ. Akt2 regulates cardiac metabolism and
cardiomyocyte survival. J Biol Chem.
2006;281(43):32841–51. https://doi.org/10.1074/jbc.
M513087200.
91. Riehle C, Abel ED. Insulin signaling and heart failure.
Circ Res. 2016;118(7):1151–69. https://doi.org/10.
1161/CIRCRESAHA.116.306206.
92. Gross DN, van den Heuvel AP, BirnbaumMJ. The role
of FoxO in the regulation of metabolism. Oncogene.
2008;27(16):2320–36. https://doi.org/10.1038/onc.
2008.25.
   18 Page 18 of 21 Curr. Treat. Options in Oncol.           (2021) 22:18 
93. Eijkelenboom A, Burgering BM. FOXOs: signalling
integrators for homeostasis maintenance. Nat Rev Mol
Cell Biol. 2013;14(2):83–97. https://doi.org/10.1038/
nrm3507.
94.• Xia P, Chen J, Liu Y, Fletcher M, Jensen BC, Cheng Z.
Doxorubicin induces cardiomyocyte apoptosis and at-
rophy through cyclin-dependent kinase 2-mediated
activation of forkhead box O1. J Biol Chem.
2020;295(13):4265–76. https://doi.org/10.1074/jbc.
RA119.011571
New study that indicates FOXO1 as a potential target in
DOXO-induced cardiotoxicity.
95. Oh J, Lee BS, Lim G, Lim H, Lee CJ, Park S, et al.
Atorvastatin protects cardiomyocyte from doxorubicin
toxicity by modulating survivin expression through
FOXO1 inhibition. J Mol Cell Cardiol. 2020;138:244–
55. https://doi.org/10.1016/j.yjmcc.2019.12.007.
96. Hill JA, Olson EN. Cardiac plasticity. N Engl J Med.
2008;358(13):1370–80. https://doi.org/10.1056/
NEJMra072139.
97. Honors MA, Kinzig KP. The role of insulin resistance in
the development of muscle wasting during cancer ca-
chexia. J Cachexia Sarcopenia Muscle. 2012;3(1):5–11.
https://doi.org/10.1007/s13539-011-0051-5.
98.•• Thackeray JT, Pietzsch S, Stapel B, Ricke-Hoch M, Lee
CW, Bankstahl JP, et al. Insulin supplementation
attenuates cancer-induced cardiomyopathy and slows
tumor disease progression. JCI Insight.
2017;2(10):e93098. https://doi.org/10.1172/jci.
insight.93098
Important evidence that describes the effect of cancer on car-
diac insulin signalling.
99. Taniyama Y, Walsh K. Elevated myocardial Akt signal-
ing ameliorates doxorubicin-induced congestive heart
failure and promotes heart growth. J Mol Cell Cardiol.
2002;34(10):1241–7. https://doi.org/10.1006/jmcc.
2002.2068.
100. Al-Shabanah OA, El-Kashef HA, Badary OA, Al-
Bekairi AM, Elmazar MM. Effect of streptozotocin-
induced hyperglycaemia on intravenous pharmaco-
kinetics and acute cardiotoxicity of doxorubicin in
rats. Pharmacol Res. 2000;41(1):31–7. https://doi.
org/10.1006/phrs.1999.0568.
101. Kurtoglu M, Maher JC, Lampidis TJ. Differential toxic
mechanisms of 2-deoxy-D-glucose versus 2-
fluorodeoxy-D-glucose in hypoxic and normoxic tu-
mor cells. Antioxid Redox Signal. 2007;9(9):1383–
90. https://doi.org/10.1089/ars.2007.1714.
102. Pajak B, Siwiak E, Soltyka M, Priebe A, Zielinski R,
Fokt I, et al. 2-Deoxy-d-glucose and its analogs: from
diagnostic to therapeutic agents. Int J Mol Sci.
2019;21(1):234. https://doi.org/10.3390/
ijms21010234.
103. Maschek G, Savaraj N, Priebe W, Braunschweiger P,
Hamilton K, Tidmarsh GF, et al. 2-deoxy-D-glucose
increases the efficacy of adriamycin and paclitaxel in
human osteosarcoma and non-small cell lung cancers
in vivo. Cancer Res. 2004;64(1):31–4. https://doi.
org/10.1158/0008-5472.can-03-3294.
104. Chen K, Xu X, Kobayashi S, Timm D, Jepperson T,
Liang Q. Caloric restriction mimetic 2-deoxyglucose
antagonizes doxorubicin-induced cardiomyocyte
death by multiple mechanisms. J Biol Chem.
2011;286(25):21993–2006. https://doi.org/10.
1074/jbc.M111.225805.
105. Cao J, Cui S, Li S, Du C, Tian J, Wan S, et al. Targeted
cancer therapy with a 2-deoxyglucose-based adria-
mycin complex. Cancer Res. 2013;73(4):1362–73.
https://doi.org/10.1158/0008-5472.CAN-12-2072.
106. Lekli I, Haines DD, Balla G, Tosaki A. Autophagy: an
adaptive physiological countermeasure to cellular se-
nescence and ischaemia/reperfusion-associated car-
diac arrhythmias. J Cell Mol Med. 2017;21(6):1058–
72. https://doi.org/10.1111/jcmm.13053.
107. Cuervo AM, Macian F. Autophagy, nutrition and im-
munology. Mol Asp Med. 2012;33(1):2–13. https://
doi.org/10.1016/j.mam.2011.09.001.
108. Kawaguchi T, Takemura G, Kanamori H, Takeyama T,
Watanabe T, Morishita K, et al. Prior starvation miti-
gates acute doxorubicin cardiotoxicity through resto-
ration of autophagy in affected cardiomyocytes. Car-
diovasc Res. 2012;96(3):456–65. https://doi.org/10.
1093/cvr/cvs282.
109. Heras-Sandoval D, Perez-Rojas JM, Hernandez-
Damian J, Pedraza-Chaverri J. The role of PI3K/AKT/
mTOR pathway in the modulation of autophagy and
the clearance of protein aggregates in neurodegener-
ation. Cell Signal. 2014;26(12):2694–701. https://
doi.org/10.1016/j.cellsig.2014.08.019.
110. Kim J, Kundu M, Viollet B, Guan KL. AMPK and
mTOR regulate autophagy through direct phosphor-
ylation of Ulk1. Nat Cell Biol. 2011;13(2):132–41.
https://doi.org/10.1038/ncb2152.
111. Laplante M, Sabatini DM. mTOR signaling in growth
control and disease. Cell. 2012;149(2):274–93.
https://doi.org/10.1016/j.cell.2012.03.017.
112. Barpe DR, Rosa DD, Froehlich PE. Pharmacokinetic
evaluation of doxorubicin plasma levels in normal
and overweight patients with breast cancer and sim-
ulation of dose adjustment by different indexes of
body mass. Eur J Pharm Sci : official journal of the
European Federation for Pharmaceutical Sciences.
2010;41(3–4):458–63. https://doi.org/10.1016/j.
ejps.2010.07.015.
113. Li Y, Wang Y, Zou M, Chen C, Chen Y, Xue R, et al.
AMPK blunts chronic heart failure by inhibiting
autophagy. Biosci Rep. 2018;38(4):BSR20170982.
https://doi.org/10.1042/BSR20170982.
114. Canto C, Auwerx J. Calorie restriction: is AMPK a key
sensor and effector? Physiology (Bethesda).
2011;26(4):214–24. https://doi.org/10.1152/
physiol.00010.2011.
115. Mitra MS, Donthamsetty S, White B, Latendresse JR,
Mehendale HM. Mechanism of protection of moder-
ately diet restricted rats against doxorubicin-induced
acute cardiotoxicity. Toxicol Appl Pharmacol.
2007;225(1):90–101. https://doi.org/10.1016/j.taap.
2007.07.018.
Curr. Treat. Options in Oncol.           (2021) 22:18 Page 19 of 21    18 
116. Lv X, Yu X, Wang Y, Wang F, Li H, Wang Y, et al.
Berberine inhibits doxorubicin-triggered cardiomyo-
cyte apoptosis via attenuating mitochondrial dys-
function and increasing Bcl-2 expression. PLoS One.
2012;7(10):e47351. https://doi.org/10.1371/journal.
pone.0047351.
117. Trites MJ, Clugston RD. The role of adipose triglycer-
ide lipase in lipid and glucose homeostasis: lessons
from transgenic mice. Lipids Health Dis.
2019;18(1):204. https://doi.org/10.1186/s12944-
019-1151-z.
118.•• Abdullah CS, Alam S, Aishwarya R, Miriyala S,
Bhuiyan MAN, PanchatcharamM, et al. Doxorubicin-
induced cardiomyopathy associated with inhibition
of autophagic degradation process and defects in mi-
tochondrial respiration. Sci Rep. 2019;9(1):2002.
https://doi.org/10.1038/s41598-018-37862-3
Time course study ofDOXO treatment showing impairment of
autophagy, mitochondrial dynamics, and bioenergetics in
both acute and chronic mouse models of DOXO- associated
cardiomyopathy.
119. Wang P, Wang L, Lu J, Hu Y, Wang Q, Li Z, et al.
SESN2 protects against doxorubicin-induced cardio-
myopathy via rescuing mitophagy and improving
mitochondrial function. J Mol Cell Cardiol.
2019;133:125–37. https://doi.org/10.1016/j.yjmcc.
2019.06.005.
120. Dhingra R, Margulets V, Chowdhury SR, Thliveris J,
Jassal D, Fernyhough P, et al. Bnip3 mediates
doxorubicin-induced cardiac myocyte necrosis and
mortality through changes in mitochondrial signal-
ing. Proc Natl Acad Sci U S A. 2014;111(51):E5537–
44. https://doi.org/10.1073/pnas.1414665111.
121. Sun A, Cheng Y, Zhang Y, Zhang Q, Wang S, Tian S,
et al. Aldehyde dehydrogenase 2 ameliorates
doxorubicin-induced myocardial dysfunction
through detoxification of 4-HNE and suppression of
autophagy. J Mol Cell Cardiol. 2014;71:92–104.
https://doi.org/10.1016/j.yjmcc.2014.01.002.
122. Zhang Y, Ren J. ALDH2 in alcoholic heart diseases:
molecular mechanism and clinical implications.
Pharmacol Ther. 2011;132(1):86–95. https://doi.org/
10.1016/j.pharmthera.2011.05.008.
123. Chen CH, Budas GR, Churchill EN, Disatnik MH,
Hurley TD, Mochly-Rosen D. Activation of aldehyde
dehydrogenase-2 reduces ischemic damage to the
heart. Science. 2008;321(5895):1493–5. https://doi.
org/10.1126/science.1158554.
124. Doser TA, Turdi S, ThomasDP, Epstein PN, Li SY, Ren
J. Transgenic overexpression of aldehyde
dehydrogenase-2 rescues chronic alcohol intake-




125. Ge W, Yuan M, Ceylan AF, Wang X, Ren J. Mito-
chondrial aldehyde dehydrogenase protects against
doxorubicin cardiotoxicity through a transient recep-
tor potential channel vanilloid 1-mediated
mechanism. Biochim Biophys Acta.
2016;1862(4):622–34. https://doi.org/10.1016/j.
bbadis.2015.12.014.
126. Cardoso S, Santos RX, Carvalho C, Correia S,
Pereira GC, Pereira SS, et al. Doxorubicin
increases the susceptibility of brain mitochondria
to Ca(2+)-induced permeability transition and
oxidative damage. Free Radic Biol Med.
2008;45(10):1395–402. https://doi.org/10.1016/
j.freeradbiomed.2008.08.008.
127. Park JH, Choi SH, Kim H, Ji ST, Jang WB, Kim JH,
et al. Doxorubicin regulates autophagy signals via
accumulation of cytosolic Ca(2+) in human cardiac
progenitor cells. Int J Mol Sci. 2016;17(10):1680.
https://doi.org/10.3390/ijms17101680.
128. Decuypere JP, Bultynck G, Parys JB. A dual role for
Ca(2+) in autophagy regulation. Cell Calcium.
2011;50(3):242–50. https://doi.org/10.1016/j.ceca.
2011.04.001.
129. Pandey S, KuoWW, Shen CY, Yeh YL, Ho TJ, Chen RJ,
et al. Insulin-like growth factor II receptor-alpha is a
novel stress-inducible contributor to cardiac damage
underpinning doxorubicin-induced oxidative stress
and perturbed mitochondrial autophagy. Am J Phys
Cell Phys. 2019;317(2):C235–C43. https://doi.org/
10.1152/ajpcell.00079.2019.
130. Xie Z, Lau K, Eby B, Lozano P, He C, Pennington B,
et al. Improvement of cardiac functions by chronic
metformin treatment is associated with enhanced
cardiac autophagy in diabetic OVE26 mice. Diabetes.
2011;60(6):1770–8. https://doi.org/10.2337/db10-
0351.
131. Xu C, Wang W, Zhong J, Lei F, Xu N, Zhang Y, et al.
Canagliflozin exerts anti-inflammatory effects by
inhibiting intracellular glucose metabolism and pro-
moting autophagy in immune cells. Biochem Phar-
macol. 2018;152:45–59. https://doi.org/10.1016/j.
bcp.2018.03.013.
132.• Verma S, Rawat S, Ho KL, Wagg CS, Zhang L, Teoh H,
et al. Empagliflozin increases cardiac energy produc-
tion in diabetes: novel translational insights into the
heart failure benefits of SGLT2 inhibitors. JACC Basic
Transl Sci. 2018;3(5):575–87. https://doi.org/10.
1016/j.jacbts.2018.07.006
Recent study suggesting the beneficial impact on cardiac func-
tion of Empagliflozin, a new antidiabetic class. The authors
evaluated cardiac energy production and substrate use in dia-
betic mice treated with Empagliflozin.
133. Hammoudi N, Jeong D, Singh R, Farhat A, Komajda
M, Mayoux E, et al. Empagliflozin improves left ven-
tricular diastolic dysfunction in a genetic model of
type 2 diabetes. Cardiovasc Drugs Ther.
2017;31(3):233–46. https://doi.org/10.1007/
s10557-017-6734-1.
134. Karlsson FH, Fak F, Nookaew I, Tremaroli V, Fager-
berg B, Petranovic D, et al. Symptomatic atheroscle-
rosis is associated with an altered gut metagenome.
Nat Commun. 2012;3:1245. https://doi.org/10.
1038/ncomms2266.
   18 Page 20 of 21 Curr. Treat. Options in Oncol.           (2021) 22:18 
135. Fu J, BonderMJ, CenitMC, Tigchelaar EF,MaatmanA,
Dekens JA, et al. The gut microbiome contributes to a
substantial proportion of the variation in blood lip-
ids. Circ Res. 2015;117(9):817–24. https://doi.org/
10.1161/CIRCRESAHA.115.306807.
136. Marques FZ, Mackay CR, Kaye DM. Beyond gut feel-
ings: how the gut microbiota regulates blood pres-
sure. Nat Rev Cardiol. 2018;15(1):20–32. https://doi.
org/10.1038/nrcardio.2017.120.
137. Tang WH, Wang Z, Kennedy DJ, Wu Y, Buffa JA,
Agatisa-Boyle B, et al. Gut microbiota-dependent tri-
methylamine N-oxide (TMAO) pathway contributes
to both development of renal insufficiency and mor-
tality risk in chronic kidney disease. Circ Res.
2015;116(3):448–55. https://doi.org/10.1161/
CIRCRESAHA.116.305360.
138. Turnbaugh PJ, Ley RE, Mahowald MA, Magrini V,
Mardis ER, Gordon JI. An obesity-associated gut
microbiome with increased capacity for energy har-
vest. Nature. 2006;444(7122):1027–31. https://doi.
org/10.1038/nature05414.
139. Wen L, Ley RE, Volchkov PY, Stranges PB, Avanesyan
L, Stonebraker AC, et al. Innate immunity and intes-
tinal microbiota in the development of type 1 diabe-
tes. Nature. 2008;455(7216):1109–13. https://doi.
org/10.1038/nature07336.
140. Qin J, Li Y, Cai Z, Li S, Zhu J, Zhang F, et al. A
metagenome-wide association study of gut micro-
biota in type 2 diabetes. Nature. 2012;490(7418):55–
60. https://doi.org/10.1038/nature11450.
141. Tang WHW, Li DY, Hazen SL. Dietary metabolism,
the gut microbiome, and heart failure. Nat Rev Car-
diol. 2019;16(3):137–54. https://doi.org/10.1038/
s41569-018-0108-7.
142. Zhu A, Sunagawa S, Mende DR, Bork P. Inter-
individual differences in the gene content of human
gut bacterial species. Genome Biol. 2015;16:82.
https://doi.org/10.1186/s13059-015-0646-9.
143. Tremaroli V, Backhed F. Functional interactions be-
tween the gut microbiota and host metabolism. Na-
ture. 2012;489(7415):242–9. https://doi.org/10.
1038/nature11552.
144. Brown JM, Hazen SL. The gut microbial endocrine
organ: bacterially derived signals driving cardiometa-
bolic diseases. Annu Rev Med. 2015;66:343–59.
https://doi.org/10.1146/annurev-med-060513-
093205.
145. Li L, Hua Y, Ren J. Short-chain fatty acid propionate
alleviates Akt2 knockout-induced myocardial con-
tractile dysfunction. Exp Diabetes Res.
2012;2012:851717. https://doi.org/10.1155/2012/
851717.
146. Antos CL, McKinsey TA, Dreitz M, Hollingsworth LM,
Zhang CL, Schreiber K, et al. Dose-dependent block-
ade to cardiomyocyte hypertrophy by histone
deacetylase inhibitors. J Biol Chem.
2003;278(31):28930–7. https://doi.org/10.1074/jbc.
M303113200.
147. Gallo P, Latronico MV, Gallo P, Grimaldi S, Borgia F,
Todaro M, et al. Inhibition of class I histone deacety-
lase with an apicidin derivative prevents cardiac hy-
pertrophy and failure. Cardiovasc Res.
2008;80(3):416–24. https://doi.org/10.1093/cvr/
cvn215.
148. Granger A, Abdullah I, Huebner F, Stout A, Wang T,
Huebner T, et al. Histone deacetylase inhibition
reduces myocardial ischemia-reperfusion injury in
mice. FASEB J. 2008;22(10):3549–60. https://doi.
org/10.1096/fj.08-108548.
149. Kong Y, Tannous P, Lu G, Berenji K, Rothermel BA,
Olson EN, et al. Suppression of class I and II histone
deacetylases blunts pressure-overload cardiac hyper-
trophy. Circulation. 2006;113(22):2579–88. https://
doi.org/10.1161/CIRCULATIONAHA.106.625467.
150. Moyal L, Goldfeiz N, Gorovitz B, Rephaeli A, Tal E,
Tarasenko N, et al. AN-7, a butyric acid prodrug,
sensitizes cutaneous T-cell lymphoma cell lines to
doxorubicin via inhibition of DNA double strand
breaks repair. Investig New Drugs. 2018;36(1):1–9.
https://doi.org/10.1007/s10637-017-0500-x.
151. Rephaeli A, Waks-Yona S, Nudelman A, Tarasenko I,
Tarasenko N, Phillips DR, et al. Anticancer prodrugs
of butyric acid and formaldehyde protect against
doxorubicin-induced cardiotoxicity. Br J Cancer.
2007;96(11):1667–74. https://doi.org/10.1038/sj.
bjc.6603781.
152. Tarasenko N, Kessler-Icekson G, Boer P, Inbal A,
Schlesinger H, Phillips DR, et al. The histone deace-
tylase inhibitor butyroyloxymethyl diethylphosphate
(AN-7) protects normal cells against toxicity of anti-
cancer agents while augmenting their anticancer ac-
tivity. Investig New Drugs. 2012;30(1):130–43.
https://doi.org/10.1007/s10637-010-9542-z.
153.• Russo M, Guida F, Paparo L, Trinchese G, Aitoro R,
Avagliano C, et al. The novel butyrate derivative phe-
nylalanine-butyramide protects from doxorubicin-
induced cardiotoxicity. Eur J Heart Fail.
2019;21(4):519–28. https://doi.org/10.1002/ejhf.
1439
Butyrate-derived molecule prevents cardiac mitochondria dys-
function in the heart.
Publisher’s note
Springer Nature remains neutral with regard to jurisdic-
tional claims in published maps and institutional
affiliations.
Curr. Treat. Options in Oncol.           (2021) 22:18 Page 21 of 21    18 
